GWM
PTGX icon

Gilpin Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Gilpin Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.27K Hold
9
– – ﹤0.01% 656
2026
Q2 		$1.1K Hold
9
– – ﹤0.01% 497
2026
Q1 		$949 Buy
9
+4
+80% +$354 ﹤0.01% 488
2025
Q4 		$437 Buy
+5
New +$409 ﹤0.01% 470

Other funds holding PTGX

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
NWMP
Noble Wealth Management PBC Greenwood Village, Colorado $223M AUM 7.64% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's PTGX Position: Q3 2026 in Review

Gilpin Wealth Management held its Protagonist Therapeutics (PTGX) position steady in Q3 2026 at 9 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #656.

Gilpin Wealth Management first reported a position in PTGX in Q4 2025 and has held it in 4 quarters since. 10 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Gilpin Wealth Management held 9 shares of Protagonist Therapeutics worth $1.27K as of Q3 2026.
  • Gilpin Wealth Management left its Protagonist Therapeutics share count unchanged in Q3 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #656 holding.
  • Gilpin Wealth Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 10 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.